| 摘要 |
Compounds of Formula I wherein; R1 is selected from the group consisting of (a) CH3, (b) NH2, (c )NHC(O)CF3, (d) NHCH3; Ar is a mono-, di-, or tri-substituted phenyl or pyridinyl (or the N-oxide thereof), wherein the substituents are chosen from the group consisting of (a) hydrogen, (b) halo, (c) C1-6alkoxy. (d) Cl6alkylthio, (e) CN, (f) C1-6alkyl, (g) C1-6fluoroalkyl, (h) N3, (i) -Co2R3, (j) hydroxy, (k) -C(R4)(R5)-OH, (l) -C1-6alkyl-CO2-R6, (m) Cl 6fluoroalkoxy; R2 is chosen from the group consisting of (a) halo, (b) C1-6alkoxy, (c) C1-6alkylthio, (d) CN, (e) C1-6alkyl, (f) Cl.6fluoroalkyl, (g) N3, (h) -Co2R7, (i) hydroxy, (j) -C(R8)(R9)-OH, (k)-Cl .6alkyl-CO2-R1 0, (1) Cl .6fluoroalkoxy, (m) NO2, (n) NR11R12, (o) NHCOR13 R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, are each independently chosen from the group consisting of (a hydrogen, and (b) C1-6alkyl, or R4 and R5, R8 and R9 or R11 and R12 together with the atom to which they are attached form a saturated monocyclic ring of 3, 4, 5, 6 or 7 atoms. These compounds are useful in treating COX-2 mediated diseases.
|
